Project Grant R56CA284683
Award Date
9/11/24
Completion Date
8/31/25
Dollars Obligated
$300K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $426,425 to Baylor College of Medicine to conduct a pilot study examining the relationship between gut microbiome composition, metabolic dysfunction-associated steatotic liver disease (MASLD), and hepatocellular carcinoma (HCC). The key objectives of this 2-year study are to: 1) characterize baseline gut microbiome diversity associated with MASLD with and without HCC, 2)...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $580,238 to the Regents of the University of Minnesota to investigate biomarkers for early detection of hepatitis B-related hepatocellular carcinoma (liver cancer) in Hispanic populations. The key objectives are to: Determine if novel immune signatures in the serum of persons with chronic hepatitis B infection and liver cancer show differential expression compared to...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $634,061 to the University of Maryland, Baltimore to study the role of tumor-associated plasmacytoid dendritic cells (TAPDC) in the tumor immune microenvironment of liver cancer or hepatocellular carcinoma (HCC) during HIV infection and immunotherapy. The key objectives are to: Investigate how TAPDC reprogram the HCC tumor immune microenvironment, and how HIV infection affects TAPDC/tumor...
This Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), will fund a pilot study to evaluate the associations of pre- and post-chemotherapy and -radiotherapy gut microbiome profiles with breast cancer recurrence and mortality. The $175,000 award will support the use of shotgun metagenome sequencing on 110 post-treatment stool samples from the Vietnam Breast Cancer Study, as well as an investigation of the impact of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $165,883 to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System Incorporated) for a 2-year research project titled "Inflammation and Hepatocellular Carcinoma: A Multiomics Approach to Improve Early Detection, Causal Inference, and Lifestyle Based Prevention." The project aims to leverage epidemiological data and advanced multi-omics analytics...
The National Center for Chronic Disease Prevention and Health Promotion, part of the Centers for Disease Control and Prevention (CDC), awarded a $750,000 Project Grant under the CDC Investigations and Technical Assistance program (CFDA 93.283) to The National Alliance For Hispanic Health. The grant, titled "LIVERWISE: HEALTHY LIVER, HEALTHY LIFE!", aims to improve liver health outcomes within the Hispanic community. The award period runs from September 30, 2024 to September 29, 2027....
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $606,839 to Weill Medical College of Cornell University to study the role of microbiota amino acid metabolism in cancer. The project aims to identify gut microbes and their genes that deplete intestinal amino acids, and evaluate how they affect the tumor microenvironment and cancer progression. The 5-year project will combine bioinformatics, metabolomics,...
This federal Project Grant award of $599,299 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at the University of Illinois to investigate the role of the enzyme hexokinase 2 (HK2) in liver fibrosis and its connection to non-alcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC). The research aims to further validate the importance of HK2 in liver fibrosis development and its impact on NASH-induced HCC, a leading cause of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $456,764 to the University of Chicago to study differences in bile acid metabolism and colonic responses between African Americans and non-Hispanic whites, and their potential connection to colorectal cancer disparities. The key objectives of this 2-year research project are to: 1) compare serum bile acid composition between the two populations, 2) perform...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $764,565 to the Sloan-Kettering Institute for Cancer Research to conduct a large prospective investigation to validate promising metabolite biomarkers for gastric cancer risk and discover novel biomarkers. The 5-year project will harmonize pre-diagnostic plasma samples and epidemiological data from ~1,200 gastric cancer cases and 1,600 matched controls across six...